Psyence Biomedical to Issue Shares for $5M PsyLabs Investment, Resulting in Near 100% Dilution and 49.98% PsyLabs Ownership
PBM sits 24% above its 52-week low of $2.42 on light trading volume (0.3× avg).
Summary
Psyence Biomedical Ltd. announced PsyLabs exercised a $5 million put option, leading to the issuance of 1.15 million PBM shares and nearly 100% dilution for existing shareholders, with PsyLabs gaining a 49.98% stake.
Key Events · Financing and Capital Events · PBM
-
Put Option Exercised
PsyLabs exercised its $5 million put option, requiring Psyence Biomedical to subscribe for PsyLabs shares in a non-cash transaction.
-
Significant Share Issuance
Psyence Biomedical will issue 1,146,159 common shares to PsyLabs, calculated using a 30-day VWAP of $4.36 per share.
-
Extreme Dilution
This issuance represents nearly 100% dilution to existing shareholders, based on the prior outstanding share count of 1,147,148 common shares.
-
Control Shift
Following the issuance, PsyLabs will beneficially own approximately 49.98% of Psyence Biomedical's issued and outstanding common shares.
Analysis · PBM · Life Sciences
This filing confirms the exercise of a previously disclosed put option by PsyLabs, resulting in a highly dilutive share-for-share exchange. The issuance of 1.15 million common shares to PsyLabs, based on a $4.36 VWAP, will nearly double the outstanding share count and grant PsyLabs a significant 49.98% ownership stake. While the company states this strengthens a strategic relationship and secures supply, the extreme dilution and substantial shift in control are significantly negative for existing shareholders. The transaction value of $5 million is nearly double the company's current market capitalization, underscoring the magnitude of this capital event.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 39.1% of the 343 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBM was trading at $3.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $2.42 to $74.94. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.